DMA-132
DMA-132 is a translation inhibitor and antiviral agent. DMA-132 can target and bind to the conserved RNA stem-loop (bulge structure) in the 5'-UTR of SARS-CoV-2, thereby blocking viral RNA translation and replication. DMA-132 can be used in research related to coronavirus disease 2019 (COVID-19) and coronavirus infections.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1160-14-1
- 分子式: C14H17N7O
- 分子量:299.33
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero E6 | CC50 |
>100 μM
|
Cytotoxicity against Vero E6 cells assessed as reduction in cell viability incubated for 96 hrs at 33°C by MTT assay.
Cytotoxicity against Vero E6 cells assessed as reduction in cell viability incubated for 96 hrs at 33°C by MTT assay.
|
34826236 |
体外実験
DMA-132 (50-100 μM; 24 h) reduces the viral titer by approximately 1000-fold in Vero E6 cells infected with hCoV OC43[1].
DMA-132 (1 μM-1 mM; 24-72 h) reduces infectious virus titers and decreases viral RNA levels in cell supernatants in a dose-dependent manner in SARS-CoV-2-infected Vero E6 cells[1].
DMA-132 (0.1-100 μM; 48 h) reduces 5'-UTR-dependent luciferase expression in Vero E6 cells co-transfected with the SARS-CoV-2 5'-UTR-FLuc luciferase reporter gene[1].
DMA-132 (500 μM) specifically binds to RNA structures (mainly the internal bulge regions of SL1, SL4, SL5a and SL6) in a cell-free system[1].
DMA-132 (1 μM-1 mM; 96 h) exhibits extremely low cytotoxicity in Vero E6 cells, with a CC50 > 100 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Vero E6 cells
-
Concentration:0.01 nM, 0.1 nM, 1 nM, 0.01 μM, 0.1 μM, 1 μM, 10 μM, 100 μM, 1 mM
-
Incubation Time:96 h
-
Result:Did not substantially reduce cell viability at concentrations < 100 μM, revealing a 50% cytotoxic concentration (CC50) of > 100 μM.
-
Cell Line:Vero E6 cells
-
Concentration:1 μM, 10 μM, 100 μM, 1 mM
-
Incubation Time:24, 48, 72 h
-
Result:Dose-dependently decreased cell-free viral RNA levels in supernatants of infected cells.
化学情報
-
CAS 番号 1160-14-1
-
分子量 299.33
-
分子式 C14H17N7O
-
SMILES
O=C(C1=C(N)N=C(N(C)C)C(C2=CC=CC=C2)=N1)NC(N)=N
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
DMA-132 関連分類
HY-189158 関連分類
Powered by Bioz